94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
SYSTEMATIC REVIEW article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1566939
This article is part of the Research Topic Precision Oncology in Checkpoint Immunotherapy: Leveraging Predictive Biomarkers for Personalized Treatment View all 13 articles
The Efficacy and Safety of PD-1/PD-L1 Inhibitors in Combination with Chemotherapy as a First-line Treatment for Unresectable, Locally Advanced, HER2-Negative Gastric or Gastroesophageal Junction Cancer: A Meta-analysis of Randomized Controlled Trials
Provisionally accepted
Wenji Pu 1
Shasha Li 1 Jinliang Zhang 1 Jijie Huang 1
JISHI LI 1
Yong Jiang 1
Zhi-yuan Xu 1 Fan Yi 1 Yuling Lan 1 Qin Xiao 2* Wenqi Chen 2*
Jing Jin 2*- 1 Shenzhen Hospital, The University of Hong Kong, Shenzhen, China
- 2 National Cancer Center, Cancer Hospital Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China
Immune checkpoint inhibitors (ICIs) plus fluorouracil-based chemotherapy (Chemo) have been approved as an initial treatment strategy for metastatic or recurrent human epidermal growth factor receptor 2 (HER2)-negative gastric cancer (GC) or gastroesophageal junction cancer (GEJC). However, since programmed cell death protein-1 (PD-1) or its ligand 1 (PD-L1) inhibitors have just recently been investigated for the treatment of unresectable GC/GEJC, there is ongoing debate regarding their safety and effectiveness for prespecified subgroups.The purpose of this research is to establish a foundation toward stratified decision-making by methodically assessing the merits and drawbacks of PD-1/PD-L1 inhibitors combined with chemo in the clinical utilization of advanced HER2-negative GC/GEJC according to certain prominent large-scale randomized controlled trials (RCTs). In addition, we limitedly explored the favorable short-term efficacy of PD-1/CTLA-4 bispecific antibodies for the above-mentioned tumors.
Keywords: advanced gastroesophageal cancer, Immune check points, PD-1/PD-L1 inhibitors, chemotherapy, Gastroesophageal adenocarcinoma, Gastric adenocarcinoma, overall survival, Meta-analysis
Received: 26 Jan 2025; Accepted: 11 Mar 2025.
Copyright: © 2025 Pu, Li, Zhang, Huang, LI, Jiang, Xu, Yi, Lan, Xiao, Chen and Jin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Qin Xiao, National Cancer Center, Cancer Hospital Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China
Wenqi Chen, National Cancer Center, Cancer Hospital Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China
Jing Jin, National Cancer Center, Cancer Hospital Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.